One year after reaching its all-time high near $126,000 in October 2025, Bitcoin now trades around $85,300, about 32% below that peak. The price fell sharply due to macroeconomic concerns and a tariff-related liquidation, bottoming near $58,000 in mid-2026 before rebounding about 45% by late September. Such drawdowns are typical for Bitcoin, with recoveries often taking 28 to 38 months. Investors should watch ETF inflows and macroeconomic developments as key factors influencing future price movements.
Bitcoin price developments provide context for cryptocurrency markets. For readers following crypto assets, here is Pluang's market snapshot as of Oct 06, 2026 15:41 WIB: among 50 major cryptocurrencies priced on Pluang, 17 rose and 32 fell today. Notable movers include COMP at Rp439.483 with a 1-day change of -3.47% and Pluang order activity of 20% Sell / 80% Buy, XLM at Rp3.859 with a 1-day change of -3.43%, and ALGO at Rp2.273 with a 1-day change of -3.40%.
Elon Musk has confirmed that his company is in discussions with Terafab, marking a potential new chip manufacturing partner alongside Intel, which has been the only named chip partner until now. This development could diversify the supply chain and e...
Parataxis Ethereum has officially canceled its planned merger with Parataxis Korea due to complications from a delisting dispute and potential large shareholder cash claims that threatened its liquidity. Both companies' boards approved the terminatio...
Sandisk holds a $93.9 billion contract backlog supported by $16.5 billion in financial guarantees and has already received $2.5 billion, reflecting strong customer commitment. The company projects an adjusted free cash flow of $8.74 billion for fisca...
Chainlink (LINK) is trading around $13.84 after pulling back from a brief surge above $15. The token maintains an ascending support line from August near $13, signaling ongoing bullish momentum. The network launched CCIP 2.0, enhancing security and s...
Verastem Inc. reported $25.1 million in net product revenues for Q2 2026 from its Avmapki Fakzynja Co-pack, used for certain ovarian cancer patients. The company is also developing a KRAS G12D inhibitor, VS-7375, targeting multiple cancers, with impo...
